The study's conclusion said treatment with narsoplimab was safe and "resulted in clinical response and favorable overall survival."
Omeros shares were down 7% on Wednesday morning.
Price: 4.41, Change: -0.29, Percent Change: -6.17
|Deutsche Bank Adjusts Northern Trust's Price Target ...|
|Berkshire Hathaway Adds Stake in Occidental Petroleu...|
|Deutsche Bank Downgrades State Street to Hold From B...|
|Wells Fargo Adjusts Fortune Brands Home & Security's...|
|Wells Fargo Adjusts Owens Corning Price Target to $8...|